Stocklytics Platform
Asset logo for symbol HLVX
Penny Stock
Asset logo for symbol HLVX



AI Deep-Learning Forecast (HLVX)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

HilleVax (HLVX) Stocklytics Forecast

HilleVax, Inc., also known as HLVX, is a pharmaceutical company specializing in the development and production of vaccines. With a strong focus on research and innovation, HilleVax aims to address the global health challenges by providing safe and effective vaccines. The company has a diversified pipeline of vaccine candidates targeting various infectious diseases, including influenza, hepatitis, and COVID-19.

Investors are eagerly following HLVX's stock price as they seek to make informed investment decisions. While it is impossible to predict the future stock price with absolute certainty, analysts and AI-driven predictions can provide valuable insights. According to industry experts, HLVX's stock price is expected to experience significant growth in the coming years, driven by the company's promising vaccine pipeline and positive clinical trial results.

add HilleVax to watchlist

Keep an eye on HilleVax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the analyst price prediction for HilleVax (HLVX) stock?

Analysts have set a target price of $30.25 for HilleVax (HLVX), based on forecasts from 8 analysts. The predicted price range extends from a high of $40 to a low of $22. This represents a potential increase of up to 2.06K% and a decrease of 1.09K% from the current price of $1.86. These forecasts are as of 2021 Mar 02.

What are the analyst ratings for HilleVax (HLVX) stock?

Currently, there are no analyst ratings available for HilleVax (HLVX), possibly due to insufficient coverage or recent updates.

What is the AI price prediction for HilleVax (HLVX) stock?

At present, there is no AI or machine-learning-based price prediction available for HilleVax (HLVX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level